Sage Therapeutics, Inc. (SAGE) Now Covered by Analysts at Royal Bank Of Canada

Royal Bank Of Canada started coverage on shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) in a research report sent to investors on Thursday morning. The brokerage issued an outperform rating and a $117.00 price objective on the biopharmaceutical company’s stock.

SAGE has been the subject of several other research reports. BidaskClub downgraded Sage Therapeutics from a buy rating to a hold rating in a research note on Wednesday, August 23rd. J P Morgan Chase & Co cut their price target on Sage Therapeutics from $99.00 to $85.00 and set an overweight rating for the company in a research note on Tuesday. Chardan Capital reaffirmed a hold rating on shares of Sage Therapeutics in a research note on Wednesday. ValuEngine raised Sage Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. Finally, Cowen and Company started coverage on Sage Therapeutics in a research note on Monday, June 12th. They set an outperform rating and a $95.00 price target for the company. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of Buy and an average price target of $86.77.

Sage Therapeutics (NASDAQ:SAGE) traded down 4.01% during midday trading on Thursday, hitting $62.25. 941,641 shares of the stock were exchanged. The stock’s market cap is $2.33 billion. Sage Therapeutics has a one year low of $38.30 and a one year high of $90.80. The firm has a 50-day moving average price of $81.85 and a 200-day moving average price of $74.87.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same period last year, the business earned ($1.08) earnings per share. On average, equities research analysts anticipate that Sage Therapeutics will post ($7.38) EPS for the current fiscal year.

WARNING: This report was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/15/sage-therapeutics-inc-sage-now-covered-by-analysts-at-royal-bank-of-canada.html.

A number of institutional investors and hedge funds have recently bought and sold shares of SAGE. BlackRock Inc. grew its holdings in Sage Therapeutics by 10,082.5% in the 1st quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock valued at $203,482,000 after buying an additional 2,835,006 shares during the period. MARSHALL WACE ASIA Ltd purchased a new stake in Sage Therapeutics in the 1st quarter valued at about $35,493,000. Marshall Wace North America L.P. purchased a new stake in Sage Therapeutics in the 1st quarter valued at about $35,493,000. Point72 Asset Management L.P. grew its holdings in Sage Therapeutics by 512.9% in the 1st quarter. Point72 Asset Management L.P. now owns 395,300 shares of the biopharmaceutical company’s stock valued at $28,094,000 after buying an additional 330,800 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Sage Therapeutics by 10.8% in the 1st quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock valued at $191,269,000 after buying an additional 261,759 shares during the period.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply